Full Publications

 

 

2017

Bubendorf L, Dafni U, Schöbel M, Finn SP, Tischler V, Sejda A, Marchetti A, Thunnissen E,. Verbeken EK, Warth A, Sansano I, Cheney T, Speel EJM, Daisuke Nonaka D, Monkhorst K, Hager H, Martorell M, Savic S, Kerr KM, Tan Q, Tsourti Z, Geiger TR, Kammler R, Schulze K, Das-Gupta A, Shames D, Peters S, Stahel RA. Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. Lung Cancer 2017. Epup ahead of print.

(ETOP Lungscape) (Journal impact factor 4.294)

 

Rosell, R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R; Ponce Aix, S, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps, C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan, E. Kammler R, Ruepp B, Rabaglio M, Kassapian, M, Karachaliou, N, Tam R, Shames, DS, Molina-Vila MA, Stahel RA, for the BELIEF collaborative group. Phase II trial of erlotinib and bevacizumab in patients with advanced non-small cell lung cancer and activating EGFR mutations (BELIEF). Lancet Respiratory Medicine 2017; 5 (5): 435-444.

(ETOP BELIEF) (Journal impact factor 15.328)

 

Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal O, Palmero Sanchez R, Villa Guzmánu JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF. for the EMPHASIS-lung collaborative group. Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer failing first line platinum-based doublet chemotherapy stratified by Veristrat good versus Veristrat poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung trial. Journal of Thoracic Oncology 2017; 12 (4): 752–762.

(ETOP EMPHASIS-lung) (Journal impact factor 5.04)

 

 

2014

Peters S, Weder W, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, O'Byrne KJ, Wrona A, Vansteenkiste J, Felip E, Marchetti A, Savic S, Lu S, Smit E, Dingemans AMC, Blackhall FH, Baas P, Camps C, Rosell R, and Stahel RA, on behalf of the ETOP Lungscape investigators. Lungscape: resected non-small cell lung cancer outcome by clinical and pathological parameters. Journal of Thoracic Oncology. 2014; 9(11):1675-1684.

(ETOP Lungscape) (Journal impact factor 5.04)

 

Blackhall FH, Peters S, Bubendorf L, Dafni U, Kerr KM, Hager H, Soltermann A, O’Byrne KJ, Dooms C, Sejda A, Hernández-Losa J, Marchetti A, Savic S, Tan Q, Thunnissen E, Speel EJM, Cheney R, Nonaka D, de Jong J, Martorell M, Letovanec I, Rosell R, and Stahel RA. Prevalence and Clinical Outcomes for Patients with ALK-Positive Resected Stage I to III Adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape Project. Journal of Clinical Oncology. 2014; 32(25):2780-7.

(ETOP Lungscape) (Journal impact factor 20.982)

 

Patton S, Normanno N, Blackhall FH, Murray S, Kerr KM, Dietel M, Filipits M, Benlloch S, Popat S, Stahel RA, and Thunnissen E. Assessing standardization of molecular testing for non-small cell lung cancer: Results of a worldwide External Quality Assessment (EQA) scheme for EGFR mutation testing. British Journal of Cancer. 2014; 111(2):413-20.

(ETOP Lungscape) (Journal impact factor 5.569)

 

 

 2011

Gridelli C, Stahel RA, Besse B, Ciardiello F, Felip E, Gasparini S, Graziano P, Rossi A, and de Marinis F. Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. Lung Cancer. 2011; 74:544-8.

(ETOP general) (Journal impact factor 3.767)

 

 

2010

Stahel RA, Baas P, Faivre-Finn C, Dooms C, Passlick B, Mazières J, Cappuzzo F, Früh M, Sorensen JB, Blackhall FH, Taron M, Gridelli C, O'Byrne KJ, and Rosell R. Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP). Lung Cancer. 2010; 68:121-4.

(ETOP general) (Journal impact factor 3.767)

 

 

 

Meeting Abstracts

 

2017

Kerr KM, Thunnissen E, Dafni U, Soltermann A, Finn SP, Bubendorf L, Verbeken E, Biernat W, Warth A, Marchetti A, Speel EJM, Pokharel S, Quinn AM, Monkhorst K,  Navarro A, Polydoropoulou V, Kammler R, Peters S,  Stahel RA, on behalf of the Lungscape Consortium. Association of programmed cell death 1 ligand (PD-L1) expression with molecular alterations in non-small cell lung cancer (NSCLC) patients (pts): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort. Ann Oncol (2017) 28 (suppl_5): mdx390.002.

(ETOP Lungscape) (Journal impact factor 11.855)

 

Kerr KM, Thunnissen E, Dafni U, Soltermann A, Finn SP, Bubendorf L, Verbeken E, Biernat W, Warth A, Marchetti A, Speel EJM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Bille Madsen A, Polydoropoulou V, Kammler R, Peters S, Stahel RA, ETOP Lungscape Consortium. Prevalence and clinical correlation of programmed cell death 1 ligand (PD-L1) expression in patients with resected non-small cell lung cancer (NSCLC): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort. Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 8516-8516.

(ETOP Lungscape) (Journal impact factor 24.008)

 

Smit EF., Peters S., Dziadziuszko R., Dafni U, Wolf J., Wasąg B., Biernat W., Finn S., Kammler R., Tsourti Z., Rabaglio M., Ruepp B., Roschitzki-Voser H., Stahel RA., Felip E. A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a HER2 mutation. The ETOP NICHE trial. Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 9070-9070.

(ETOP NICHE) (Journal impact factor 24.008)

 

Peters S, Stahel RA, Kassapian M, Guckenberger M, Felip E, De Langen AJ, Huber RM, Roschitzki-Voser H, Piguet AC, De Ruysscher D. A feasibility trial evaluating the addition of nivolumab to standard first-line chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: The ETOP 6-14 NICOLAS trial. Ann Oncol (2017) 28 (suppl_2): mdx092.009.

(ETOP NICOLAS) (Journal impact factor 11.855)

 

Finn S, Letovanec I, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel EJ, Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernandez-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, Navarro A, Felip E, Warth A, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dienemann H, Dziadziuszko R, Vansteenkiste J, Geiger T, Sherlock J, Schageman J, Dafni U, Kammler R, Kerr K, Thunnissen E, Peters S, Stahel R, On Behalf Of The ETOP Lungscape Consortium. Evaluation of NGS and rt-PCR methods for ALK assessment in European NSCLC patients: Results from the ETOP Lungscape project. Journal of Thoracic Oncology. 2017; 12 (Suppl 1): S501–S502.

(ETOP Lungscape) (Journal impact factor 5.04)

 

2016

Finn S, Letovanec I, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel EJ, Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernandez-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, Navarro A, Felip E, Warth A, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dienemann H, Dziadziuszko R, Vansteenkiste J, Geiger T, Sherlock J, Schageman J, Dafni U, Kammler R, Kerr K, Thunnissen E, Peters S, Stahel R, On Behalf Of The ETOP Lungscape Consortium. Evaluation of NGS and rt-PCR methods for ALK assessment in European NSCLC patients: Results from the ETOP Lungscape project. Journal of Thoracic Oncology. 2017; 12 (Suppl 1): S501–S502.

(ETOP Lungscape) (Journal impact factor 5.04)

 

De Ruysscher D, Pujol JL, Popat S, Reck M, Le Pechoux C, Liston A, Speiser Dd, Coukos G, Kammler R, Dafni U, Tsourti Z, Roschitzki H, Finlayson M, Piguet AC, Ruepp B, Maibach R, Stahel RA, Peters S. STIMULI: A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after standard of care chemo-radiotherapy conducted by ETOP and IFCT Annals of Oncology. 2016; 27 (Suppl 6): vi493–vi496, 2016.

(ETOP STIMULI) (Journal impact factor 9.269)

 

Soltermann A, Rulle U, Dafni U, Verbeken E, Thunnissen E, Warth A, Cheney R, Sejda A, Speel EJ, Bille Madsen L, Nonaka D, Navarro A, Sansano I, Marchetti A, Finn S, Kammler R, Schulze K, Bubendorf L, Stahel RA, on behalf of Lungscape. Prevalence and clinical associations of PTEN loss in non-small cell lung carcinoma (NSCLC) patients (pts) of the European Thoracic Oncology Platform (ETOP) Lungscape cohort. Annals of Oncology. 2016; 27 (Suppl 6): vi526–vi544, 2016.

(ETOP Lungscape) (Journal impact factor 9.269)

 

Rosell R, Karachaliou N, Giménez-Capitán A, Codony-Servat C, Gautschi O, Felip E, Curioni-Fontecedro A, Peters S, Ponce-Aix S, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Favaretto A, Kammler R, Dafni U, Tsourti Z, Molina-Vila MA, Stahel RA. The role of BRCA1 and AEG1 mRNA expression in advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR activating and pretreatment T790M mutations receiving the combination of erlotinib plus bevacizumab (E+B) in the BELIEF trial. Proceedings of the AACR. 2016; 57 (A), #270.

 

 

2015

Stahel RA, Dafni U, Gautschi O, Felip E, Curioni-Fontecedro A, Peters S, Massutí B, Cardenal F, Aix SP, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Carcereny E, Sanchez Ronco M, Molina MA, Rosell R. A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial. Presented at the European Cancer Congress 2015 in Vienna, AT. Eur J Cancer. 2015; 51 (suppl 3):S711.

(ETOP 2-11 BELIEF) (Journal impact factor 6.163)

 

Kerr KM, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Gately K, Biernat W, Vliegen L, Hernandez Losa J, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Molina MA, Shames DS, Peters S, Stahel R, On behalf of the ETOP Lungscape investigators

Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project. Presented at the European Cancer Congress 2015 in Vienna. Eur J Cancer. 2015; 51 (suppl 3): S595.

(ETOP Lungscape) (Journal impact factor 6.163)

 

Bubendorf L, Dafni U, Finn SP, Warth A, Savic S, Thunnissen E, Sejda A, Verbeken EK, Tischler V, Marchetti A, Sansano I, Speel EJM, Cheney R, Nonaka D, Monkhorst K, Di Lorito A, Consuelo Calabuig M, Reidy M, Hager H, Mathieson W, Martorell M, Baas P, Dienemann H, Smit EF, Blackhall FH Dingemans AMC, Felip E, Adjei A, Meldgaard P, Weder W, Vansteenkiste J, Dziadziuszko R, Tsourti Z, Kerr KM, Schulze K, Das-Gupta A, Peters S, Stahel RA. Prevalence and clinical association of MET gene amplification in patients with NSCLC: Results from the ETOP Lungscape Project. Presented at WCLC 2015 in Denver, CO. Journal of Thoracic Oncology. 2015; 10(9):S247.

(ETOP Lungscape)(Journal impact factor 5.04)

 

Letovanec I, Peters S, Tsourti Z, Finn SP, Soltermann A, Bubendorf L, Speel EJM, Marchetti A, Nonaka D, Hager H, Martorell M, Monkhorst K, Sejda A, Cheney R, Sansano I, Verbeken EK, Tischler V, Savic S, Di Lorito A, Consuelo Calabuig M, Felip E, Adjei A, Warth A, Baas P, Meldgaard P, Blackhall FH, Dingemans AMC, Dienemann H, Dziadziuszko R, Vansteenkiste J, Kammler R, Dafni U, Kerr KM, Thunnissen E, Stahel RA. Evaluation of RT-PCR methodology for ALK assessment in patients with NSCLC in Europe: Results from the ETOP Lungscape Project. Presented at WCLC 2015 in Denver, CO. Journal of Thoracic Oncology. 2015; 10(9):S693-S94.

(ETOP Lungscape)(Journal impact factor 5.04)

 

Peters S, Smit EF, Dafni U, Aix SP, Massuti B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Floriani IC, Kassapian M, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Zielinski C, Gregorc V, Stahel RA and EMPHASIS Collaborative Group. Randomized phase III trial of Erlotinib vs. Docetaxel in patients with advanced squamous cell non-small cell lung cancer (SqNSCLC) failing first line platinum based doublet chemotherapy stratified by VeriStrat Good vs VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS trial. Presented at ASCO 2015 in Chicago, IL. Journal of Clinical Oncology. 2015; 33(suppl 15): 8049.

(ETOP 3-12 EMPHASIS)(Journal impact factor 20.982)

 

 

2014

Bubendorf L, Dafni U, Tischler V, Finn SP, Biernat W, Verbeken E, Hager H, Murtra N, Thunnissen E, Nonaka D, Warth A, Speel EJM, Savic S, Martorell M, Tsourti Z, Schulze K, Das Gupta A, Kerr KM, Peters S, and Stahel RA. Prevalence and clinical outcomes for patients with MET protein expression in patients with non-small cell lung cancer in Europe: Results from the European Thoracic Oncology Platform Lungscape Project. Presented at ESMO 2014 in Madrid, Spain. Annals of Oncology. 2014; 25 (suppl 4):iv418.

(ETOP Lungscape) (Journal impact factor 9.269)

 

 

2013

Kerr KM, Thunnissen E, Blackhall FH, Dafni U, Bubendorf L, Hager H, Soltermann A, O'Byrne KJ, Marchetti A, Dooms C, Sejda A, Sansano I, Nonaka D, Cheney R, De Jong J, Speel EJM, Jantus-Lewintre E, Zhang YJ, Stahel RA, and Peters S, on behalf of ETOP. ALK immunohistochemistry and fluorescence in-situ hybridization in lung adenocarcinomas from the ETOP Lungscape tumour cohort. Presented at 15th World Conference on Lung Cancer 2013 in Sydney, Australia. Journal of Thoracic Oncology. 2013; 8(2):S318-319.

(ETOP Lungscape) (Journal impact factor 5.04)

 

Peters S, Weder W, Meldgaard P, O'Byrne KJ, Wrona A, Dooms C, Hernandez-Losa J, Marchetti A, Nicolson M, Tan Q, Smit EF, Dingemans AMC, Savic S, Blackhall FH, Baas P, Jantus-Lewintre E, Kerr KM, Dafni U, Rosell R, Stahel RA, and European Thoracic Oncology Platform (ETOP). The European Thoracic Oncology Platform Lungscape project: Clinical outcome data as a basis for molecular correlations in resected non-small cell lung cancer. Presented at ASCO 2013 in Chicago, IL. Journal of Clinical Oncology. 2013; 31(suppl 15):7514.

(ETOP Lungscape) (Journal impact factor 20.982)

 

 

2012

Peters S, Dafni O, Bubendorf L, Meldgaard P, O'Byrne KJ, Wrona A, Weder W, Canela M, Malatesta S, Vansteenkiste JF, Dingemans AMC, Nicolson MC, Savic S, Baas P, Peck R, Lu S, Smit EF, Jantus-Lewintre E, Rosell R, and Stahel RA, on behalf of ETOP. The European Thoracic Oncology Platform Lungscape project. A way to bridge non-small cell lung cancer molecular characteristics and clinical data. Presented at ESMO 2012 in Vienna, Austria. Annals of Oncology. 2012; 23(suppl 9):ix385.

(ETOP Lungscape) (Journal impact factor 9.269)

 

Blackhall FH, Peters S, Kerr KM, O'Byrne KJ, Hager H, Sejda A, Soltermann A, Dooms C, Felip E, Marchetti A, Speel EJM, Price N, Savic S, De Jong J, Martorell M, Thunnissen E, Bubendorf L, Dafni O, Rosell R, and Stahel RA, on behalf of ETOP. Prevalence and clinical outcomes for patients with ALK gene rearrangement in Europe: Preliminary results from the European Thoracic Oncology Platform Lungscape project. Presented at ESMO 2012 in Vienna, Austria. Annals of Oncology. 2012; 23(suppl 9):ix73.

(ETOP Lungscape) (Journal impact factor 9.269)

 

Stahel RA. Lung Cancer: The European Thoracic Oncology Platform. Presented at ESMO 2012 in Vienna, Austria. Annals of Oncology. 2012; 23(suppl 9):ix58.

(ETOP general) (Journal impact factor 9.269)

 

Normanno N, Patton S, Blackhall FH, Murray S, Kerr KM, Dietel M, Filipits M, Benlloch S, Stahel RA, and Thunnissen E. Results of the second pilot external quality assurance scheme for somatic EGFR mutation testing in non-small cell lung cancer (NSCLC). Presented at ESMO 2012 in Vienna, Austria. Annals of Oncology. 2012; 23(suppl 9):ix86.

(ETOP Lungscape) (Journal impact factor 9.269)

 

Thunnissen E, Kerr KM, Bubendorf L, Nonaka D, Blackhall FH, Kammler R, Speel EJM, De Jong J, Martorell M, and Stahel RA, on behalf of ETOP. External quality assessment for ALK immunohistochemistry testing in lung adenocarcinoma within the European Thoracic Oncology Platform Lungscape project. Presented at ESMO 2012 in Vienna, Austria. Annals of Oncology. 2012; 23(suppl 9):ix80.

(ETOP Lungscape) (Journal impact factor 9.269)

 

Stahel RA, Blackhall FH, Peters S, Bubendorf L, Dafni O, Kerr KM, Taron M, Thunnissen E, Weder W, and Rosell R. The Lungscape project. Presented at ELCC 2012 in Geneva, Switzerland. Journal of Thoracic Oncology. 2012; 7(6):S13-S13.

(ETOP Lungscape) (Journal impact factor 5.04)

 

Peters S, Blackhall FH, Taron M, Rosell R, Hiltbrunner A, Maibach R, King R, and Stahel RA. ETOP Data system: Combining the comprehensive Lungscape database with a clinical trails platform. Presented at TAT 2012 in Amsterdam, Netherlands. Annals of Oncology. 2012; 23(suppl 1):i41.

(ETOP Lungscape) (Journal impact factor 9.269)

 

Stahel RA, Peters S, Blackhall FH, Bubendorf L, Dafni U, Kerr KM, Taron M, Thunnissen E, Weder W, Smit E, and Rosell R. ETOP activity in the field of biomarkers and predictors. Presented at BTOG 2012 in Dublin, Ireland. Lung Cancer. 2012; 77(S1):S16-S17.

(ETOP general) (Journal impact factor 3.767)

 

2011

Blackhall FH, Peters S, Kerr KM, Kulig K, Bubendorf L, Thunnissen E, Dziadziuszko R, O’Byrne KJ, Baas P, Weder W, Taron M, Rosell R, and Stahel RA. ALK Gene Rearrangement: Prevalence and clinical outcomes in patients with non-small cell lung cancer (NSCLC) in Europe – A European Thoracic Oncology Group (ETOP) Lungcape Study. Presented at the 14th World Conference on Lung Cancer (WCLC 2011) in Amsterdam, Netherlands. Journal of Thoracic Oncology. 2011; 6(6 Suppl 2):S903-S1688.

(ETOP Lungscape) (Journal impact factor 5.04)

 

Peters S, Blackhall FH, Boffetta P, Kerr KM, Taron M, Bubendorf L, Ciardiello F, Rosell R, Weder W, King R, and Stahel RA. Building a Comprehensive Database for the Lungscape Project: A Way to Bridge Genomics and Clinical Practice in the European Thoracic Oncology Platform (ETOP). Presented at the 14th World Conference on Lung Cancer (WCLC 2011) in Amsterdam, Netherlands. Journal of Thoracic Oncology. 2011; 6(6 suppl 2):S903-S1688.

(ETOP Lungscape) (Journal impact factor 5.04)

 

Stahel RA, Blackhall FH, Peters S, Kerr KM, Taron M, Bubendorf L, Weder W, Boffetta P, Ciardiello F, and Rosell R, on behalf of ETOP. Lungscape - a project of the European Thoracic Oncology Platform (ETOP). Presented at TAT 2011 in Paris, France. Annals of Oncology. 2011; 22(suppl 3):iii26–iii28.

(ETOP Lungscape) (Journal impact factor 9.269)